Those pharmaceutical companies whose goal is to generate novel innovative drugs are faced with the challenge that only a fraction of the compounds tested in clinical trials eventually become a registered drug. This problem of attrition is compounded by the fact that the clinical trial or development stage is by far the most costly phase of bringing a new drug to market, consuming around 80 per cent of the total spend. Transgenic technology represents an attractive approach to reducing the attrition rate of compounds entering clinical trials by increasing the quality of the target and compound combinations making the transition from discovery into development. Transgenic technology can impact at many points in the discovery process, including target identification and target validation, and provides models designed to alert researchers early to potential problems with drug metabolism and toxicity, as well as providing better models for human diseases. In target identification, transgenic animals harbouring large DNA fragments can be used to narrow down genetic regions. Genetic studies often result in the identification of large genomic regions and one way to decrease the region size is to do complementation studies in transgenic animals using, for example, inserts from bacterial artificial chromosome (BAC) clones. In target validation, transgenic animals can be used for in vivo validation of a specific target. Considerable efforts are being made to establish new, rapid and robust tools with general utility for in vivo validation, but, so far, only transgenic animals work reliably on a wide range of targets. Transgenic animals can also be used to generate better disease models. Predictive animal models to test new compounds and targets will significantly speed up the drug discovery process and, more importantly, increase the quality of the compounds taken further in the research and development process. Humanised transgenic animals harbouring the human target molecule can be used to understand the effect of a compound acting on the human target in vivo. Also, models mimicking human drug metabolism will provide a means of assessing the effect of human-specific metabolites and of understanding the pharmacokinetic properties of potential drugs. In toxicology studies, transgenic animals are providing more predictive models. A good example of this are those models routinely used to look for carcinogenicity associated with new compounds.
BACKGROUND
Homeostasis in humans is dependent on communication between different cell types via cell-cell interactions and signalling through hormone and nervous systems. Genetic and/or environmental factors can act to disrupt this natural homeostasis and thereby cause diseases to develop. Over time, somatic mutations accumulate in an individual's genome so that their genetic make-up is continuously varying, both spatially and temporally. The environment of an individual is also continuously changing. Thus, the body's ability to remain in status quo is being continuously challenged both from the outside and from within, and, furthermore, the body's natural defences against such challenges weaken with age. To discover novel treatments for human disease, all of these factors must be taken into consideration. Challenging experimental animals with specific environmental factors has been possible for a long time. With the development of transgenic technology, it is now also possible to induce specific mutations in somatic or germ cells to mimic genetic alterations.
Pharmaceutical companies are faced with the challenge that only about ten per cent of compounds tested in clinical trials eventually make it to the market (and, out of these, only a minority will generate a significant profit). The cost of identifying a new drug is immense -US$800m -and 80 per cent of this cost is spent in clinical trials and development. Transgenic technology has the potential to influence the attrition rate in pharmaceutical research and development by increasing the quality of both targets and compounds. This may include, for the target, the demonstration that the specific target is rate limiting for disease development or progression in vivo and, at the same time, not rate limiting for vital physiological functions. For the compound, transgenic technology can be used to develop tools to show that the new potential drug has the desired effect in vivo (eg animals containing the human target molecule or better models of human disease). By using animals humanised for drug metabolism pathways or toxicology reporter mice, it may be possible to exclude compounds causing overt metabolism or toxicological problems.
IMPACT ON BASIC RESEARCH
Ever since the first gene addition experiment using the microinjection technology was described by Gordon and co-workers in the early 1980s, 1,2 the impact of transgenic technology on basic research has been great. To date, more than 21,000 papers have been published in Medline indexed journals using the transgenic and knockout technologies. More than 1,500 of these papers were published in some of the most prestigious journals, such as Cell, Nature or Science. Although the first gene addition experiments were described by Jaenish and co-workers in 1976, 3 it was not until the publications from the laboratories of Brinster in 1982 and 1983, 4,5 describing the spectacular giant mice overexpressing growth hormone, that the technology gained general awareness. Ever since, transgenic technology has facilitated great progress in research fields such as immunology, 6 oncology, 7 developmental biology, 8 neuroscience, 9 cardiovascular research 10,11 and many others.
The technical challenges associated with generating a given transgenic animal depends on the model required. A 'standard' transgenic animal overexpressing a particular gene and a 'standard' knockout are both relatively straightforward to generate in a wellequipped laboratory today. More complex conditional models using cre/lox or the tetracycline inducible system are more complicated and still only mastered routinely in a limited number of laboratories. A built-in feature of transgenic animals is that the genetic alteration introduced is inherited and only needs to be generated once. Breeding can produce many animals, allowing researchers to perform their own studies and also to distribute them more widely to the research community. Several possible avenues are therefore available for obtaining transgenic animals: internal production, external repositories (eg the Jackson Laboratory) and other academic groups. The Jackson Laboratory has a large collection of animals generated inhouse and by academic groups 12 and these can be requested by interested researchers. There are several databases containing information pertaining to the numerous transgenic animals which have been generated, but a good place to start is TBase.
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DRUG DISCOVERY PROCESS
The process of generating new drugs ( Figure 1 ) needs to be described in some detail in order to be able to explain where transgenic technology can make an impact. The objective of the first step, 'Target Identification' (TI), is to discover
Transgenic technology increases quality of targets and compounds Huge impact on basic research a molecular target that may be appropriate for pharmaceutical intervention to reverse, stabilise or prevent disease. There are several approaches to discovering new potential drug targets. Two conceptually different approaches are the genomic approach and the genetic approach. The genomic approach 14 looks at the differential expression of genes in, for example, normal versus disease tissue or gene expression changes after a compound is added to the culture medium or to the animal. Today, many groups use some sort of microarray technology 15 or proteomics 16 to identify the changes in gene expression. This approach assumes that the expression of relevant targets will be different in diseased tissue or after treatment. The challenges with this technology 17 are that a number of current drug targets are not up-or down-regulated in disease, only changes of a certain magnitude can be detected due to practical constraints, the change in expression may be a cause or a consequence of the disease and, in many cases, the number of 'false positive' genes will be high. Downstream analysis after array experiments turns out to be a major challenge.
The genetic approach is more long term and more labour intensive. One of the main hurdles for this approach is that most major diseases are polygenic and the genetic analysis is therefore complicated. 25 This is one of the first examples where a gene contributing to a polygenic human disease has been identified using linkage analysis. Genetic studies in humans are costly and long term. An interesting complement to human genetic studies is genetic analysis in model organisms. A challenge is to make sure that the phenotype identified in the animal is relevant to the human disease and that the biological pathways are similar in humans and in the experimental species. An interesting publication compared the loci linked to hypertension identified in mice with those in humans. Six loci were found in mice and four of these were concordant with the human loci. 26 This finding becomes even more interesting when comparing the costs and times for human and mouse genetic studies. The mouse study could be performed five times faster and cost just one per cent of that of the human study. 27 The huge advantage of using genetic approaches over expression profiling genomic approaches is that there is a clear link between a genetic alteration and a disease phenotype; the gene identified is clearly a cause, not a consequence, of disease. The disadvantage is time.
Gene expression analysis can be used to discover new targets Genetic studies will disclose the linkage between genes and disease Figure 1 : Use of transgenic technology to enhance drug discovery The next step of drug discovery is often called 'Target Validation' (TV). The essence of target validation is to determine whether the target identified in TI is rate limiting for a given disease's progression/ induction and, at the same time, not essential for vital physiological functions. TV data to support a chosen target are generated using many different approaches, often performed in parallel, and it is worth pointing out that ultimate validation of the target (along with the compound selected to interact with it) only occurs when the new potential drug is tested in patients (phase IIB). Very early in the TV phase, when a large number of targets must be processed, bioinformatics and experiments in cultured cells are the usual techniques deployed. Before entering the 'lead optimisation' phase (see below), when large resources are engaged in chemistry, results from modulating the target in vivo should be available.
The next two phases are high throughput screening (HTS) followed by 'hits to leads' (H2L). For HTS, an assay compatible with automation needs to be developed which is then used to identify those chemical compounds which interact in the desired way with the proposed drug target. 28 Hundreds of thousands, sometimes millions, of compounds are tested rapidly and 'hits' are identified. These 'hit' compounds are then evaluated by chemists to give a subset of 'leads', which form the starting point for chemistry. In the next phase, 'lead optimization' (LO), the lead molecules are modified to enhance efficacy, safety, specificity and pharmacokinetic properties. This stage requires testing of the substance in systems which resemble the human context as closely as possible. Efficacy, specificity, drug metabolism, pharmacokinetics and toxicology all must be determined. After a safe and effective compound has been identified, testing in humans can start. First, small numbers of healthy volunteers will receive the substance (phase I), followed, secondly, by a small number of patients (phase II) and, eventually, a large patient cohort (phase III). The different phases of clinical trials are designed to generate safety and efficacy data for new compounds.
As described above, one of the great challenges in pharmaceutical research is to decrease the attrition rate for candidate drugs in clinical trials. The likelihood of success for a new potential drug is related to the quality of the target (rate limiting for disease initiation/progression, not vital for normal physiological homeostasis) and the quality of the chemical compound (effective at modulating the human target molecule, specific, having optimal kinetics, and safe). The quality of the target and the compound are equally important and both of these can be enhanced by the use of appropriate transgenic technologies.
IMPACT ON TARGET IDENTIFICATION
New drug targets can be identified using a number of different approaches, as described above. One very interesting approach in the post-human genome sequencing era 29, 30 is the genetic analysis of human and model organisms. In genetic studies, a major challenge is to narrow down the genetic region to a size that will allow proper unbiased analysis of all the candidate genes in the region. In practice, this currently means that the genetic study has to deliver a region containing not many more than five candidate genes. Complementation studies using appropriate transgenic animals have been used to narrow genetic regions. 31 The concept is to introduce the large region identified by genetics as a series of smaller fragments (isolated from BACs) into a mouse strain displaying the phenotype followed in the genetic study (fragments of up to 200 kilobases can be readily isolated from BAC clones and then used to make transgenic animals). The phenotype of these BAC transgenics is then assessed to see which of the genomic fragments carried the critical gene(s) capable of influencing the phenotype being monitored. The use of overlapping genomic fragments isolated Validated molecular targets; rate limiting for disease development but redundant for physiological functions Complementation studies using transgenic systems can narrow genetic regions from BACs has also been successfully employed to narrow down regions to less than the size of a single BAC insert.
One novel possibility for increasing the genetic diversity of, and inducing random mutations in, the genome is Nethylinitrosourea (ENU) mutagenesis. 32 This represents an attractive approach for reducing polygenic diseases to monogenic traits and for identifying genetic loci having the greatest impact on a given polygenic disease. This approach has been used on a large scale and interesting phenotypes have been discovered.
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IMPACT ON TARGET VALIDATION
Target validation is a continuous critical process starting early in the discovery phase. Different validation methods have to be used during different stages of this process. In the very early phases, when selections have to be made between a large number of targets, bioinformatics tools and cultured cells can be used. There very quickly becomes a need for in vivo TV data before large amounts of resource are invested in the potential target. Considerable efforts are being made to identify rapid, reliable and general tools for in vivo validation, but, so far, only transgenic animals work reliably on a wide range of targets. Final 'validation' of a target and potential drug combination is not achieved until the new potential drug is tested in clinical trials.
A common requirement in the TV phase is the production of genetically modified animals that either overexpress (gene addition) or no longer possess the target (knockout animals). These animals provide in vivo functional data on a potential target which are often lacking. Nowadays, the alteration of expression of the target gene in genetically modified animals can be achieved with different levels of sophistication. The most rapid transgenic animal which can be produced is the one that overexpresses the transgene either ubiquitously or in a tissue-specific manner. A large number of tissue-specific promoters have now been used to restrict transgene expression to different cell types. [35] [36] [37] [38] [39] [40] [41] [42] Two options for inhibiting gene function in a relatively rapid and specific way are to overexpress either a dominant negative transgene or an anti-sense cDNA. 43 An example where the dominant negative approach was used successfully is the model for epidermolysis bullosa. 44 These approaches have only been successful in a limited number of cases.
Different systems are available to regulate expression of transgenes using non-physiological inducers. The first inducible systems used in transgenic animals were the metallothionein promoter 4, 5 and the phosphoenolpyrovatecarboxykinase promoter. 45 These systems were difficult to regulate and there were problems with background expression levels. The most widely used system for the regulation of transgenes today is the tetracycline system, [46] [47] [48] which has been used in a number of successful studies. [49] [50] [51] [52] The ecdysone system 53 and systems for the artificial dimerisation of molecules 54, 55 have also been developed, but the broad utility for regulating transgenes still has to be proven. In addition, fusion proteins between an effector protein (eg Cre) and a ligand-binding domain of a steroid receptor have been used to control the activity of genes (see section on Cre/lox below).
In the early days of gene targeting, all knockouts produced were full standard knockouts. These mutant animals lack a given gene's function from inception and throughout their lives. This work has yielded great insights into the in vivo functions of a wide range of genes, including developmental genes, 56, 57 growth factors, [58] [59] [60] [61] molecules involved in signalling transduction 62 and many more. More recently, the desire to be able to make tissue-restricted and/or inducible knockouts has grown. The most obvious reason for this is the need to overcome embryonic lethality of the homozygous null animals, but other reasons include avoidance of the induction of compensatory mechanisms due to chronic ENU mutation screens may reduce polygenic disease to monogenic traits Use of tetracycline systems to regulate transgenes absence of a gene-encoded function, avoidance of developmental phenotypes and the better mimicking of the type of gene expression changes occurring in lateonset human pathophysiologies. The most widely used system today is the cre/lox system from bacteriophage p1, [63] [64] [65] but the flp/frt system from yeast 66 has also been used successfully. Both systems require expression of the site-specific recombinase and introduction of recombinase recognition sites into the target genes. Control is achieved at the level of recombinase expression with the use of transient delivery methods or tissuespecific or inducible promoters. A number of tissue-specific and inducible cre lines have been generated and a comprehensive list can be found on the Internet. 67 The cre/lox system has now been used in a number of successful studies to generate null mutations in specific genes in particular cell types [68] [69] [70] and at certain time points. [71] [72] [73] [74] One approach being used to generate knockouts that are regulated both spatially and temporally combines the cre and modified oestrogen ligand-binding domain (LBD) systems. In this case, a tissue-specific promoter drives the expression of a fusion protein composed of a mutant form of the ligand-binding part of the oestrogen receptor and the cre enzyme. The LBD-cre fusion protein is then expressed only in a subset of cells governed by the characteristics of the promoter. This protein remains sequestered and inactive until tamoxifen is given to the animals. Tamoxifen-induced cre activity then mutates the target gene, but only in those cell types where the LBD-cre protein is expressed. [75] [76] [77] [78] [79] Using this, or similar systems, may allow generation of the 'ideal' knockout model for many pharmaceutical studies: an inducible, tissue-specific knockout which does not suffer from mosaicism.
NEW OPTIMAL DISEASE MODELS
To minimise the attrition rate in clinical trials, potential drugs for most diseases need to be tested in experimental systems that resemble human physiology and pathology as closely as possible. One way to achieve this is to introduce genetic modifications to make high-fidelity animal models resembling human pathology. The degree of comparability between the models and the human disease can be determined both functionally and morphologically, but also by using comparisons with expression profiles from human pathological tissue. In general, the closer the match, the greater the predictive value of using the disease models. In some diseases, it may not be possible to mimic the complete human pathology and, for others, it might be more desirable to create a model of a specific biological process such as angiogenesis, metastasis or plaque rupture. The latter are all processes which are believed to be good 'targets' for intervention. It should also be noted that these processes are not solely pathological (eg metastasis) but also physiological (eg angiogenesis).
Transgenic technology has resulted in the development of a number of disease models and some of these have allowed the testing of new treatment paradigms.
Alzheimer's disease
Alzheimer's disease is a progressive neurodegenerative disease. No animal models existed for the disease before transgenic technology was employed. Today, several transgenic models have been established. These models resemble much of the human pathology and are frequently used in the search for new therapeutic opportunities. In 1999, a paper was published by Schenk et al. in Nature 80 where a new approach for therapy was tested in the transgenic mouse. Immunisation of Amyloid precursor protein (APP) transgenic mice with the protein Aâ42 before disease became established resulted in disease prevention and, if performed on older animals, inhibited disease progression. This study using transgenic mice suggests that vaccination against Alzheimer's disease could have potential as a therapeutic approach.
The cre/lox system is used for conditional knockouts Optimal disease models generated by transgenic technology
Huntington's disease
In this inherited disease, the patients have an expanded CAG repeat in the gene coding for huntingtin 20 and the size of the expansion is inversely correlated to the age of onset of disease. Transgenic mice have been used to test the concept that the repeats are the cause of the disease. Mice transgenic for the huntingtinencoding gene containing an expanded CAG repeat show many of the characteristics of the human disease. These transgenic animals have also been used as a model to test new therapeutic approaches. By crossing the huntingtin transgenic mice to animals transgenic for a dominant negative caspase-1 transgene, it could be demonstrated that inhibition of caspase-1 could delay onset of symptoms and prolong survival in the transgenic mice. 81 
Cardiovascular disease
Transgenic animals have been very important for studying the pathology of cardiovascular disease 10, 11 and for developing treatments. The understanding of obesity, lipoprotein regulation, insulin resistance, hypertension and minimisation of infarction size after post-ischaemic reperfusion have all been advanced by the use of transgenic technology. The need for relevant disease models is especially great in cardiovascular disease because the pathogenic process is so long, making it a difficult disease in which to measure any beneficial effects of a potential new therapy.
Ordinary mice do not develop atherosclerosis because of high levels of high-density lipoprotein (HDL) and low low-density lipoprotein (LDL) levels. Mutation of the ApoE gene, 82 that is critical for uptake of chylomicrons and very low-density lipoprotein (VLDL) particles, results in a model that develops atherosclerotic lesions histologically similar to those found in humans. Deletion of the LDL receptor gene alone, 83 or in combination with the ApoE gene, 84 can further refine the phenotype.
The double knockout animals have high VLDL levels and lower HDL levels. One difference between this mouse model and humans is that lesions are mainly seen in the female animals, whereas lesions are much more common in men than in premenopausal women. Another difference between mouse and humans is in the editing of the apolipoprotein ApoB100. This is carried out by the editing enzyme apobec-1, resulting in ApoB48. In humans, apobec-1 is not expressed in liver, whereas it is in mice. Knocking out the apobec-1 gene and breeding it onto the LDLr -/-and ApoE -/-background to generate a triple knockout gives animals with an even better lipoprotein profile and the gender distribution of lesions now mirrors that seen in the human situation.
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A common complication after myocardial infarctions in humans is cardiac failure. The use of transgenic animals has greatly facilitated research trying to discover the pathogenesis in cardiac failure. Knockout of the muscle LIM protein has resulted in a new model for dilated cardiomyotrophy and heart failure. 86 
Oncology
In oncology, transgenic and knockout animals have been instrumental in understanding the function of oncogenes and tumour suppressor genes. 7 In addition to these fundamental studies, transgenic technology has also been used in more applied research that may be closer to clinical applications.
Mechanisms for tumour progression and metastasis Fatal outcome of malignant disease is often related to metastasis of the primary tumour. Understanding the underlying mechanisms behind metastasis could provide valuable therapeutic opportunities. The role for adhesion molecules has been studied in a model with very defined multistage tumour progression based on transgenic expression of the SV40 large T antigen in beta cells of the pancreas (Rip1Tag2 model).
7 Double transgenic animals Molecular mechanism and potential treatment for Huntington's disease
Stepwise refinement of models for atherosclerosis expressing a truncated dominant negative E-cadherin gene on the Rip1Tag2 transgenic background showed the essential role for E-cadherin in tumour progression and metastasis. 87 The essential role for another cell adhesion molecule, NCAM, in metastasis was demonstrated in a cross between the Rip1Tag2 model and a NCAM knockout. 88 Angiogenesis Inhibition of angiogenesis is currently one of the biggest opportunities for new cancer therapies. Inhibitors have already been identified which act on specific mechanisms of angiogenesis and it has become apparent that they may be of importance at different stages of tumour progression. This suggestion is based on further work with the Rip1Tag2 multistage tumour model that was introduced above. The substances tested all showed distinct efficacy profiles on the different tumour stages tested, 89 suggesting that different angiogenesis inhibitors should be used at specific disease stages.
Ras in melanomas
Expression of the transgene H-Ras V12G in animals whose INK4a tumour suppressor gene has been knocked out results in formation of malignant invasive melanomas. The Ras transgene was expressed using a system regulated by administration of tetracycline (see above). Withdrawal of tetracycline results in downregulation of the Ras transgene and also regression of the large tumours. 90 This model is being used to study the mechanisms behind tumour regression in general and the role for Ras in tumour maintenance in particular. It also demonstrates that Ras could be a good pharmaceutical target, at least for advanced melanomas where prognosis is usually poor.
SAFETY AND PHARMACOKINETIC MODELS
It is not only desirable to mimic human pathology but it is also very useful to mimic the human body's response to compounds in a model system. One way of achieving this is by introducing human genes into the mouse context. The genes introduced might be the human target genes themselves or human drug metabolism genes (or relevant human genes for which there are no mouse counterparts). Human CYP4B1 has been expressed in mice and shown to be active. 91 A number of drug metabolising P450 genes have been mutated in mice (for references, see Gonzales and Kimura 92 ). Mutations in specific P450s have also been used in order to understand their role in toxic events eg CYP 1A2, 93 2E1 94 and 1B1. [95] [96] [97] One area where the use of transgenic models is already well established is in the area of compound toxicity and, in particular, carcinogenicity. Several models now exist which have the potential to provide early warning of compound carcinogenicity. Further development and use of such models that respond more rapidly to carcinogens (six to nine months instead of two years) would also have the added benefit that they would lead to a significant reduction in the number of animals used in the studies. The value of these was recently investigated in a large, coordinated, multicentre evaluation where four different transgenic models were evaluated for their potential to predict the carcinogenicity of different compounds in humans. 98 The results of this study showed that two models in particular (the RasH2 model and the p53 +/-model) were promising, although further evaluation is needed. These models responded to known human carcinogens and may serve as a complement to the conventional twoyear rat studies.
FUTURE PERSPECTIVES
Improving the quality of target and compound combinations progressing along the drug discovery pipeline is a priority for drug companies in order to reduce and refocus the money they have to spend on bringing quality medicines to market. One way of addressing this Transgenic systems have been used to understand metastasis, angiogenesis, oncogenes and tumour suppressor genes Humanisation of mice for drug targets and drug metabolising pathways will provide more predictive animal models quality issue is to harness the power of transgenic technology. Using this technology, an exciting array of animal models specifically designed to address the function of targets and the action of compounds can be generated.
Currently, most pharmaceutical companies operate to a 'high quantity' model where relatively large numbers of targets, mainly identified through bioinformatics and expression profiling efforts, are validated to varying extents and progressed to the HTS stage resulting in multiple lead series for each. Lead compounds for each series are then used in clinical trials where the attrition rate is generally high. Success in this type of operation is achieved by keeping the numbers of targets screened high, as well as the number of compound series entering the clinical trial phase. This is extremely costly, due to attrition, and it is the belief of the authors that the greater use of transgenic models could reduce the required throughput for achieving success and, thereby, significantly impact on costs. 23. Wooster, R., Bignell, G., Lancaster, J. et al.
Paradigm shift from a 'high quantity' model to a 'high quality' drug discovery
